ThursdayNov 04, 2021 12:49 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial The trial is set to commence in 2022, subject to a favorable review by the FDA The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase…

Continue Reading

ThursdayNov 04, 2021 12:15 pm

Could This Music Studio’s Fundraiser Signal Investor Confidence in Psychedelics Industry?

While the therapeutic psychedelic industry segment grows, plenty of institutional investors seem to be seeing plenty of opportunities in companies that address the needs of the core players in the psychedelics space. Such support directed at ancillary businesses is a tacit acknowledgment that an industry is headed towards maturity and permanency. That trajectory towards maturity gives investors confidence that they may also see decent returns from the ancillary companies, as one music studio has discovered. Wavepaths was created solely to come up with music customized for psychedelic therapy.  The studio bagged $4.5 million in a funding round that closed last…

Continue Reading

WednesdayNov 03, 2021 3:00 pm

Psychedelics Group Dispatches First Batch of Grants in Support of Entheogenic User Education

Plant Medicine Coalition (“PMC”), a nonprofit based in Washington D.C. has issued about $50,000 in grants to about 12 groups in D.C. The funds are intended to facilitate those community groups in their efforts to spread awareness about plant medicine and how people can benefit from it. PMC traces its origins to the leader of the group, which spearheaded the campaign that saw entheogenic plants as well as fungi decriminalized in the capital during the elections in November last year. The money that PMC issued to the community groups was provided by a wellness company called Dr. Bronner’s. This company…

Continue Reading

TuesdayNov 02, 2021 1:00 pm

New Study Questions Purported Value of Classical Music During Psychedelic Therapy

A study has found that playing overtone-based music in psychedelic therapy is more beneficial than playing classical music. For some time now, psychedelic therapy has made use of Western classical music, with some cited works even recommending the genre’s use. However, new research has found that individual differences in music preference may influence therapeutic outcomes in sessions that involve the use of music. Justin C. Strickland and his colleagues Matthew W. Johnson and Albert Garcia-Romeu carried out an analysis of data collected from an open-label study on the use of psilocybin in stopping smoking, in order to assess the impact…

Continue Reading

MondayNov 01, 2021 3:00 pm

City Council of Easthampton Approves Psychedelics Reform Measure

Last week, the city council of Easthampton, Massachusetts, passed a psychedelics initiative that calls for some drugs and entheogenic substances to be decriminalized. The initiative, which was approved in a 7 to 0 vote, had been filed by Owen Zaret, a member of the City Council. The effort was spearheaded by Bay Staters for Natural Medicine (baystatersnm.org), a group of grassroots volunteers that has passed near-identical resolutions in three other Massachusetts cities. After the vote, Zaret stated in an interview that he felt indebted to the council for being forward thinking, noting that this progress would allow individuals to access…

Continue Reading

FridayOct 29, 2021 11:44 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Transforming Treatment of Fibromyalgia and Chronic Pain Conditions

In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a member Commenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as the company Fibromyalgia affects millions globally, but existing approved treatments have limited efficacy and/or cause significant side effects Tryp aims to remedy this, alleviating the suffering of millions of patients In February of 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company, appointed Dr.…

Continue Reading

FridayOct 29, 2021 11:30 am

A Rundown of Ongoing Psychedelics Clinical Studies

The psychedelics space has grown significantly in the last few years, becoming a full-fledged industry with many verticals that range from specialized healthcare services to digital therapeutics and supply chain solutions. Drug discovery and development is arguably the sector’s most observed vertical given that the approval of psychedelic drugs through the clinical trial pipeline is a one-way ticket to revenue for any companies in this space. Below is a list of some of the clinical trials being conducted in the psychedelics space. Ongoing phase 1 clinical trials Ceruvia Lifesciences The company is currently conducting clinical trials for its synthetic psilocybin…

Continue Reading

ThursdayOct 28, 2021 12:30 pm

Psilocybin: Why and How It Should Be Rescheduled

Scientific and public interest in psychedelic substances such as MDMA and psilocybin has been growing, as more research on the substances is conducted. However, the federal prohibition of these substances has become a hindrance to the advancement of research on psychedelics, despite the commercial investment in psychedelic treatments and growing acceptance by the public. One of the most studied psychedelics is psilocybin, which is a compound that can be produced by many fungi species including hallucinogenic mushrooms. This compound was designated as a breakthrough therapy in 2018 and 2019 by the FDA, to acknowledge its safety as well as its…

Continue Reading

WednesdayOct 27, 2021 2:15 pm

Harvard Law School Hosts Webinar to Discuss Psychedelics Policy Reform

A few weeks ago, advocates of psychedelic reform discussed the decriminalization of drugs and decreasing stigma surrounding the use of these substances during a webinar hosted by Harvard Law School. The webinar coincided with the launch of the Project on Psychedelics Law and Regulation by the Petrie-Flom Center for Health Policy. The project is a three-year initiative to study the social, legal and economic implications of psychedelic substances. Earl F. Blumenauer, a Democratic U.S. Representative in Congress and longtime marijuana reform advocate, stated in his opening remarks that he hopes that the historic progress on psychedelic decriminalization seen in Oregon…

Continue Reading

WednesdayOct 27, 2021 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Is ‘One to Watch’

The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions Through an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and Substances Dealer’s License Mydecine has a five-year master collaboration research agreement with Johns Hopkins University to research novel psychedelic therapies for mental health and addiction disorders Research out of Johns Hopkins University has shown promising efficacy data using psilocybin as a smoking cessation treatment with…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000